SEC Info - Bone Biologics Corp - ‘10-Q’ for 6/30/15

SEC Info℠

Home

My Interests

Help

Please Sign In

Bone Biologics Corp – ‘10-Q’ for 6/30/15 – ‘EX-101.CAL’

On: Friday, 8/14/15, at 4:25pm ET · For: 6/30/15 · Accession #: 1493152-15-3724 · File #: 0-53078

Previous ‘10-Q’: ‘10-Q’ on 5/15/15 for 3/31/15 · Next: ‘10-Q’ on 11/16/15 for 9/30/15 · Latest: ‘10-Q’ on 5/14/24 for 3/31/24 · 18 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/14/15  Bone Biologics Corp               10-Q        6/30/15   64:6.9M                                   M2 Compliance/FA

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    318K 
 2: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML     17K 
 3: EX-10.1     Material Contract                                   HTML     20K 
 4: EX-10.2     Material Contract                                   HTML     20K 
 5: EX-10.3     Material Contract                                   HTML     19K 
 6: EX-10.4     Material Contract                                   HTML     26K 
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 9: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
10: EX-32.2     Certification -- §906 - SOA'02                      HTML     20K 
44: R1          Document and Entity Information                     HTML     38K 
34: R2          Condensed Consolidated Balance Sheets               HTML     75K 
42: R3          Condensed Consolidated Balance Sheets               HTML     41K 
                (Parenthetical)                                                  
46: R4          Condensed Consolidated Statements of Operations     HTML     63K 
                (Unaudited)                                                      
59: R5          Condensed Consolidated Statements of Cash Flows     HTML    101K 
                (Unaudited)                                                      
36: R6          The Company                                         HTML     30K 
41: R7          Summary of Significant Accounting Policies          HTML     53K 
31: R8          Property and Equipment                              HTML     28K 
24: R9          Accounts Payable and Accrued Expenses               HTML     26K 
60: R10         Commitments and Contingencies                       HTML     38K 
48: R11         Notes Payable to Related Party                      HTML     35K 
47: R12         Notes Payable                                       HTML     52K 
52: R13         Stockholders' Equity                                HTML     56K 
53: R14         Stock-Based Compensation                            HTML     62K 
51: R15         Income Taxes                                        HTML     27K 
54: R16         Related Party Transactions                          HTML     29K 
43: R17         Subsequent Events                                   HTML     48K 
45: R18         Summary of Significant Accounting Policies          HTML     93K 
                (Policies)                                                       
50: R19         Summary of Significant Accounting Policies          HTML     26K 
                (Tables)                                                         
64: R20         Property and Equipment (Tables)                     HTML     26K 
56: R21         Accounts Payable and Accrued Expenses (Tables)      HTML     26K 
38: R22         Notes Payable to Related Party (Tables)             HTML     29K 
49: R23         Notes Payable (Tables)                              HTML     31K 
40: R24         Stockholders' Equity (Tables)                       HTML     46K 
21: R25         Stock-Based Compensation (Tables)                   HTML     57K 
57: R26         The Company (Details Narrative)                     HTML     46K 
61: R27         Summary of Significant Accounting Policies          HTML     39K 
                (Details Narrative)                                              
27: R28         Summary of Significant Accounting Policies -        HTML     28K 
                Schedule of Antidilutive Securities Excluded from                
                Computation of Earnings Per Share (Details)                      
26: R29         Property and Equipment (Details Narrative)          HTML     21K 
29: R30         Property and Equipment - Schedule of Property and   HTML     29K 
                Equipment (Details)                                              
30: R31         Accounts Payable and Accrued Expenses - Schedule    HTML     31K 
                of Accounts Payable and Accrued Expenses (Details)               
32: R32         Commitments and Contingencies (Details Narrative)   HTML    100K 
20: R33         Notes Payable to Related Party (Details Narrative)  HTML     36K 
55: R34         Notes Payable to Related Party - Notes Outstanding  HTML     34K 
                (Principal and Interest) Including Unamortized                   
                Discount, with MTF Related Party (Details)                       
37: R35         Notes Payable (Details Narrative)                   HTML     79K 
39: R36         Notes Payable - Schedule of Note Payable (Details)  HTML     40K 
23: R37         Stockholders' Equity (Details Narrative)            HTML     63K 
63: R38         Stockholders' Equity - Schedule of Outstanding      HTML     75K 
                Unexercised Common Stock Warrants (Details)                      
17: R39         Stock-Based Compensation (Details Narrative)        HTML     30K 
33: R40         Stock-Based Compensation - Schedule of Stock        HTML     49K 
                Option Activity (Details)                                        
58: R41         Stock-Based Compensation - Schedule of Stock        HTML     29K 
                Option (Details)                                                 
22: R42         Stock-Based Compensation - Schedule of Non-Vested   HTML     45K 
                Options (Details)                                                
25: R43         Income Taxes (Details Narrative)                    HTML     24K 
28: R44         Related Party Transactions (Details Narrative)      HTML     51K 
35: R45         Subsequent Events (Details Narrative)               HTML     63K 
62: XML         IDEA XML File -- Filing Summary                      XML    101K 
19: EXCEL       IDEA Workbook of Financial Reports                  XLSX     64K 
11: EX-101.INS  XBRL Instance -- boneb-20150630                      XML    874K 
13: EX-101.CAL  XBRL Calculations -- boneb-20150630_cal              XML    122K 
14: EX-101.DEF  XBRL Definitions -- boneb-20150630_def               XML    388K 
15: EX-101.LAB  XBRL Labels -- boneb-20150630_lab                    XML    869K 
16: EX-101.PRE  XBRL Presentations -- boneb-20150630_pre             XML    566K 
12: EX-101.SCH  XBRL Schema -- boneb-20150630                        XSD    153K 
18: ZIP         XBRL Zipped Folder -- 0001493152-15-003724-xbrl      Zip    106K

‘EX-101.CAL’ — XBRL Calculations — boneb-20150630_cal

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://bonebiologics.com/role/DocumentAndEntityInformation" xlink:href="boneb-20150630.xsd#DocumentAndEntityInformation" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/BalanceSheets" xlink:href="boneb-20150630.xsd#BalanceSheets" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/BalanceSheetsParenthetical" xlink:href="boneb-20150630.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/StatementsOfOperations" xlink:href="boneb-20150630.xsd#StatementsOfOperations" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/StatementsOfCashFlows" xlink:href="boneb-20150630.xsd#StatementsOfCashFlows" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/Company" xlink:href="boneb-20150630.xsd#Company" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="boneb-20150630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/PropertyAndEquipment" xlink:href="boneb-20150630.xsd#PropertyAndEquipment" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/AccountsPayableAndAccruedExpenses" xlink:href="boneb-20150630.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/CommitmentsAndContingencies" xlink:href="boneb-20150630.xsd#CommitmentsAndContingencies" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/NotesPayableToRelatedParty" xlink:href="boneb-20150630.xsd#NotesPayableToRelatedParty" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/NotesPayable" xlink:href="boneb-20150630.xsd#NotesPayable" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/StockholdersEquity" xlink:href="boneb-20150630.xsd#StockholdersEquity" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/Stock-basedCompensation" xlink:href="boneb-20150630.xsd#Stock-basedCompensation" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/IncomeTaxes" xlink:href="boneb-20150630.xsd#IncomeTaxes" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/RelatedPartyTransactions" xlink:href="boneb-20150630.xsd#RelatedPartyTransactions" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/SubsequentEvents" xlink:href="boneb-20150630.xsd#SubsequentEvents" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="boneb-20150630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="boneb-20150630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/PropertyAndEquipmentTables" xlink:href="boneb-20150630.xsd#PropertyAndEquipmentTables" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="boneb-20150630.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/NotesPayableToRelatedPartyTables" xlink:href="boneb-20150630.xsd#NotesPayableToRelatedPartyTables" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/NotesPayableTables" xlink:href="boneb-20150630.xsd#NotesPayableTables" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/StockholdersEquityTables" xlink:href="boneb-20150630.xsd#StockholdersEquityTables" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/Stock-basedCompensationTables" xlink:href="boneb-20150630.xsd#Stock-basedCompensationTables" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/CompanyDetailsNarrative" xlink:href="boneb-20150630.xsd#CompanyDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="boneb-20150630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="boneb-20150630.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="boneb-20150630.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:href="boneb-20150630.xsd#PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="boneb-20150630.xsd#AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="boneb-20150630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/NotesPayableToRelatedPartyDetailsNarrative" xlink:href="boneb-20150630.xsd#NotesPayableToRelatedPartyDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/NotesPayableToRelatedParty-NotesOutstandingPrincipalAndInterestIncludingUnamortizedDiscountWithMtfRelatedPartyDetails" xlink:href="boneb-20150630.xsd#NotesPayableToRelatedParty-NotesOutstandingPrincipalAndInterestIncludingUnamortizedDiscountWithMtfRelatedPartyDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/NotesPayableDetailsNarrative" xlink:href="boneb-20150630.xsd#NotesPayableDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/NotesPayable-ScheduleOfNotePayableDetails" xlink:href="boneb-20150630.xsd#NotesPayable-ScheduleOfNotePayableDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/StockholdersEquityDetailsNarrative" xlink:href="boneb-20150630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/StockholdersEquity-ScheduleOfOutstandingUnexercisedCommonStockWarrantsDetails" xlink:href="boneb-20150630.xsd#StockholdersEquity-ScheduleOfOutstandingUnexercisedCommonStockWarrantsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="boneb-20150630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/Stock-basedCompensation-ScheduleOfStockOptionActivityDetails" xlink:href="boneb-20150630.xsd#Stock-basedCompensation-ScheduleOfStockOptionActivityDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/Stock-basedCompensation-ScheduleOfStockOptionDetails" xlink:href="boneb-20150630.xsd#Stock-basedCompensation-ScheduleOfStockOptionDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/Stock-basedCompensation-ScheduleOfNon-vestedOptionsDetails" xlink:href="boneb-20150630.xsd#Stock-basedCompensation-ScheduleOfNon-vestedOptionsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/IncomeTaxesDetailsNarrative" xlink:href="boneb-20150630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="boneb-20150630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://bonebiologics.com/role/SubsequentEventsDetailsNarrative" xlink:href="boneb-20150630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="boneb-20150630.xsd#boneb_AccruedInterestExpense" xlink:label="loc_bonebAccruedInterestExpense"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_bonebAccruedInterestExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation"/>

<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims"/>

<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesGainLoss"/>

<link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesGainLoss" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>

<link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties"/>

<link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>

<link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCharges"/>

<link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCharges" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/Company" xlink:title="00000006 - Disclosure - The Company"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Summary of Significant Accounting Policies"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/PropertyAndEquipment" xlink:title="00000008 - Disclosure - Property and Equipment"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000009 - Disclosure - Accounts Payable and Accrued Expenses"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/CommitmentsAndContingencies" xlink:title="00000010 - Disclosure - Commitments and Contingencies"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/NotesPayableToRelatedParty" xlink:title="00000011 - Disclosure - Notes Payable to Related Party"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/NotesPayable" xlink:title="00000012 - Disclosure - Notes Payable"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders' Equity"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/Stock-basedCompensation" xlink:title="00000014 - Disclosure - Stock-Based Compensation"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/RelatedPartyTransactions" xlink:title="00000016 - Disclosure - Related Party Transactions"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/PropertyAndEquipmentTables" xlink:title="00000020 - Disclosure - Property and Equipment (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000021 - Disclosure - Accounts Payable and Accrued Expenses (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/NotesPayableToRelatedPartyTables" xlink:title="00000022 - Disclosure - Notes Payable to Related Party (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/NotesPayableTables" xlink:title="00000023 - Disclosure - Notes Payable (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/StockholdersEquityTables" xlink:title="00000024 - Disclosure - Stockholders' Equity (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/Stock-basedCompensationTables" xlink:title="00000025 - Disclosure - Stock-Based Compensation (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/CompanyDetailsNarrative" xlink:title="00000026 - Disclosure - The Company (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000029 - Disclosure - Property and Equipment (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000030 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000031 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000032 - Disclosure - Commitments and Contingencies (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/NotesPayableToRelatedPartyDetailsNarrative" xlink:title="00000033 - Disclosure - Notes Payable to Related Party (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/NotesPayableToRelatedParty-NotesOutstandingPrincipalAndInterestIncludingUnamortizedDiscountWithMtfRelatedPartyDetails" xlink:title="00000034 - Disclosure - Notes Payable to Related Party - Notes Outstanding (Principal and Interest) Including Unamortized Discount, with MTF Related Party (Details)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/NotesPayableDetailsNarrative" xlink:title="00000035 - Disclosure - Notes Payable (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/NotesPayable-ScheduleOfNotePayableDetails" xlink:title="00000036 - Disclosure - Notes Payable - Schedule of Note Payable (Details)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="loc_us-gaapSecuredDebtCurrent"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_us-gaapSecuredDebtCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" weight="-1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000037 - Disclosure - Stockholders' Equity (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/StockholdersEquity-ScheduleOfOutstandingUnexercisedCommonStockWarrantsDetails" xlink:title="00000038 - Disclosure - Stockholders' Equity - Schedule of Outstanding Unexercised Common Stock Warrants (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000039 - Disclosure - Stock-Based Compensation (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/Stock-basedCompensation-ScheduleOfStockOptionActivityDetails" xlink:title="00000040 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/Stock-basedCompensation-ScheduleOfStockOptionDetails" xlink:title="00000041 - Disclosure - Stock-Based Compensation - Schedule of Stock Option (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/Stock-basedCompensation-ScheduleOfNon-vestedOptionsDetails" xlink:title="00000042 - Disclosure - Stock-Based Compensation - Schedule of Non-Vested Options (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000043 - Disclosure - Income Taxes (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000044 - Disclosure - Related Party Transactions (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://bonebiologics.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000045 - Disclosure - Subsequent Events (Details Narrative)"/>

</link:linkbase>

18 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/26/24  Bone Biologics Corp.              S-1/A                  3:393K                                   M2 Compliance LLC/FA
 2/23/24  Bone Biologics Corp.              S-1/A                  7:1.3M                                   M2 Compliance LLC/FA
 2/21/24  Bone Biologics Corp.              10-K       12/31/23   63:6.3M                                   M2 Compliance LLC/FA
 1/30/24  Bone Biologics Corp.              S-1                   64:9.1M                                   M2 Compliance LLC/FA
11/20/23  Bone Biologics Corp.              10-K/A     12/31/22   14:425K                                   M2 Compliance LLC/FA
 6/13/23  Bone Biologics Corp.              S-1/A                  6:1M                                     M2 Compliance LLC/FA
 6/06/23  Bone Biologics Corp.              S-1/A                  6:1M                                     M2 Compliance LLC/FA
 5/01/23  Bone Biologics Corp.              S-1                    5:758K                                   M2 Compliance LLC/FA
 3/30/23  Bone Biologics Corp.              10-K       12/31/22   58:5.5M                                   M2 Compliance LLC/FA
10/05/22  Bone Biologics Corp.              S-1/A      10/04/22   59:8M                                     M2 Compliance LLC/FA
10/04/22  Bone Biologics Corp.              S-1/A                 59:8M                                     M2 Compliance LLC/FA
 9/23/22  Bone Biologics Corp.              S-1                   58:7.9M                                   M2 Compliance LLC/FA
 3/15/22  Bone Biologics Corp.              10-K       12/31/21   59:5M                                     M2 Compliance LLC/FA
10/07/21  Bone Biologics Corp.              S-1/A                 60:9.2M                                   M2 Compliance LLC/FA
10/06/21  Bone Biologics Corp.              S-1/A                 59:8.2M                                   M2 Compliance LLC/FA
 8/30/21  Bone Biologics Corp.              S-1/A                 60:7.8M                                   M2 Compliance LLC/FA
 6/28/21  Bone Biologics Corp.              S-1                   71:5.9M                                   M2 Compliance LLC/FA
 4/15/21  Bone Biologics Corp.              10-K       12/31/20   63:4.3M                                   M2 Compliance LLC/FA

↑Top

Filing Submission 0001493152-15-003724 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Bone Biologics Corp – ‘10-Q’ for 6/30/15 – ‘EX-101.CAL’

On: Friday, 8/14/15, at 4:25pm ET · For: 6/30/15 · Accession #: 1493152-15-3724 · File #: 0-53078

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘EX-101.CAL’ — XBRL Calculations — boneb-20150630_cal

This Exhibit is an XBRL XML File.

18 Subsequent Filings that Reference this Filing

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents